Literature DB >> 11099687

Reactive oxygen species and acute renal failure.

K A Nath1, S M Norby.   

Abstract

Acute renal failure is commonly due to acute tubular necrosis (ATN), the latter representing an acute, usually reversible loss of renal function incurred from ischemic or nephrotoxic insults occurring singly or in combination. Such insults instigate a number of processes-hemodynamic alterations, aberrant vascular responses, sublethal and lethal cell damage, inflammatory responses, and nephron obstruction-that initiate and maintain ATN. Eventually, reparative and regenerative processes facilitate the resolution of renal injury and the recovery of renal function. Focusing mainly on ischemic ATN, this article reviews evidence indicating that the inordinate or aberrant generation of reactive oxygen species (ROS) may contribute to the initiation and maintenance of ATN. This review also discusses the possibility that ROS may instigate adaptive as well as maladaptive responses in the kidney with ATN, and raises the possibility that ROS may participate in the recovery phase of ATN.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11099687     DOI: 10.1016/s0002-9343(00)00612-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  98 in total

1.  Toll-like receptor 4 regulates early endothelial activation during ischemic acute kidney injury.

Authors:  Jianlin Chen; Reji John; James A Richardson; John M Shelton; Xin J Zhou; Yanxia Wang; Qing Qing Wu; John R Hartono; Pamela D Winterberg; Christopher Y Lu
Journal:  Kidney Int       Date:  2010-10-06       Impact factor: 10.612

2.  Early interleukin 6 production by leukocytes during ischemic acute kidney injury is regulated by TLR4.

Authors:  Jianlin Chen; John R Hartono; Reji John; Michael Bennett; Xin Jin Zhou; Yanxia Wang; Qingqing Wu; Pamela D Winterberg; Glenn T Nagami; Christopher Y Lu
Journal:  Kidney Int       Date:  2011-06-01       Impact factor: 10.612

3.  SOD1 and MitoTEMPO partially prevent mitochondrial permeability transition pore opening, necrosis, and mitochondrial apoptosis after ATP depletion recovery.

Authors:  Huan Ling Liang; Filip Sedlic; Zeljko Bosnjak; Vani Nilakantan
Journal:  Free Radic Biol Med       Date:  2010-08-22       Impact factor: 7.376

4.  Receptor-mediated endocytosis is a Trojan horse in light-chain nephrotoxicity.

Authors:  Karl A Nath
Journal:  J Am Soc Nephrol       Date:  2010-06-17       Impact factor: 10.121

5.  Oxidative Stress and Metabolism: The NF-Erythroid 2 p45-Related Factor 2:Kelch-like ECH-Associated Protein 1 System and Regulatory T Lymphocytes in Ischemic AKI.

Authors:  Christopher Y Lu; Natalia de Albuquerque Rocha
Journal:  J Am Soc Nephrol       Date:  2015-08-20       Impact factor: 10.121

6.  Renal-targeting triptolide-glucosamine conjugate exhibits lower toxicity and superior efficacy in attenuation of ischemia/reperfusion renal injury in rats.

Authors:  Yu Fu; Qing Lin; Tao Gong; Xun Sun; Zhi-Rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2016-07-11       Impact factor: 6.150

7.  Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1.

Authors:  Qing Qing Wu; Yanxia Wang; Martin Senitko; Colin Meyer; W Christian Wigley; Deborah A Ferguson; Eric Grossman; Jianlin Chen; Xin J Zhou; John Hartono; Pamela Winterberg; Bo Chen; Anapam Agarwal; Christopher Y Lu
Journal:  Am J Physiol Renal Physiol       Date:  2011-02-02

8.  Arginase-2 mediates renal ischemia-reperfusion injury.

Authors:  Wesley M Raup-Konsavage; Ting Gao; Timothy K Cooper; Sidney M Morris; W Brian Reeves; Alaa S Awad
Journal:  Am J Physiol Renal Physiol       Date:  2017-05-17

9.  C-reactive protein exacerbates renal ischemia-reperfusion injury.

Authors:  Melissa A Pegues; Mark A McCrory; Abolfazl Zarjou; Alexander J Szalai
Journal:  Am J Physiol Renal Physiol       Date:  2013-03-27

10.  IRF-1 promotes inflammation early after ischemic acute kidney injury.

Authors:  Yanxia Wang; Reji John; Jianlin Chen; James A Richardson; John M Shelton; Michael Bennett; Xin J Zhou; Glenn T Nagami; Ying Zhang; Qing Qing Wu; Christopher Y Lu
Journal:  J Am Soc Nephrol       Date:  2009-05-14       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.